Glenmark rides COVID-19 wave, all eyes on debt reduction
Glenmark's revenue in India grew about 11 percent in nine months to December 2020 compared to a less than 1 percent expansion in industry sales during the same time
April 07, 2021 / 09:34 AM IST
Glenmark Pharmaceuticals did well to move quickly on the COVID-19 opportunity. It was the first company in India to receive the regulatory approval for oral antiviral medication drug Favipiravir to treat mild to moderate COVID-19. The drug helped the company to maintain sales momentum in India even as the pandemic weighed on the industry’s growth. Thanks to its early launch Glenmark's Favipiravir continued to have a large market share.
Glenmark’s revenue in India grew about 11 percent in nine months till December 2020...